<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03636256</url>
  </required_header>
  <id_info>
    <org_study_id>NANODOCE-2017-02</org_study_id>
    <nct_id>NCT03636256</nct_id>
  </id_info>
  <brief_title>Evaluation of NanoDoce® in Participants With Urothelial Carcinoma</brief_title>
  <official_title>Phase 1/2 Trial Evaluating the Safety and Tolerability of NanoDoce® Injection and Intravesical Instillation in Subjects With Urothelial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NanOlogy, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>US Biotest, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NanOlogy, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial studying the administration of NanoDoce as a direct injection to the
      bladder wall immediately after tumor resection and as an intravesical instillation. All
      participants will receive NanoDoce, and will be evaluated for safety and tolerability, as
      well as the potential effects of NanoDoce on urothelial carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this clinical trial, subjects with high-risk non-muscle invasive bladder cancer (NMIBC) or
      muscle invasive bladder cancer (MIBC), will receive NanoDoce. Subjects will be stratified
      into two treatment groups, Group 1 (NMIBC) and Group 2 (MIBC). All subjects will receive
      NanoDoce injected into the index tumor resection site on the bladder wall, immediately
      following transurethral resection of the bladder tumor (TURBT), followed by an initial
      NanoDoce intravesical instillation.

      Once the TURBT resection site is healed (approximately 1 month), Group 1 (NMIBC) subjects
      will proceed to a 3-month Induction period (6 weekly NanoDoce intravesical instillations,
      followed by 6 weeks of rest). After the Induction period, following confirmation of
      non-recurrence, Group 1 subjects will proceed to a 3-month Maintenance period (3 weekly
      NanoDoce intravesical instillations, followed by 9 weeks of rest).

      After NanoDoce direct injection and the initial intravesical instillation, Group 2 subjects
      will proceed to institutional standard of care and will not receive Induction of Maintenance
      intravesical instillations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2019</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Open-label, dose rising trial consisting of a dose escalation phase and a dose confirmation phase for direct injection doses. In the dose escalation phase, subjects will be enrolled in sequential cohorts of three subjects starting at the lowest concentration. The dose determined to be most suitable for further evaluation will enroll additional subjects to total up to 12 subjects at that dose level.
The study will also dose escalate Groups 1 and 2 for the intravesical instillation of NanoDoce concentrations (2.0 and 3.0 mg/mL).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (safety and tolerability)</measure>
    <time_frame>Up to End of Treatment (Month 6 for Group 1 and Day 45 for Group 2)</time_frame>
    <description>Treatment Emergent Adverse Events will include laboratory assessments, physical examination findings, and vital signs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the plasma concentration versus time curve (AUC) of NanoDoce</measure>
    <time_frame>Up to End of Treatment (Month 6 for Group 1 and Day 45 for Group 2)</time_frame>
    <description>Plasma samples will be collected to characterize the pharmacokinetics of NanoDoce.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Peak plasma concentration (Cmax) of NanoDoce</measure>
    <time_frame>Up to End of Treatment (Month 6 for Group 1 and Day 45 for Group 2)</time_frame>
    <description>Plasma samples will be collected to characterize the pharmacokinetics of NanoDoce.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time at which peak plasma concentration is observed (Tmax) of NanoDoce.</measure>
    <time_frame>Up to End of Treatment (Month 6 for Group 1 and Day 45 for Group 2)</time_frame>
    <description>Plasma samples will be collected to characterize the pharmacokinetics of NanoDoce.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Recurrence</measure>
    <time_frame>Up to End of Treatment (Month 6 for Group 1 and Day 45 for Group 2)</time_frame>
    <description>No evidence of disease as defined by cystoscopy, cytology, and if indicated, biopsy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Urinary Bladder Neoplasm</condition>
  <condition>Urinary Bladder Cancer</condition>
  <condition>Urogenital Neoplasms</condition>
  <condition>Urologic Neoplasms</condition>
  <condition>Urologic Cancer</condition>
  <condition>Malignant Tumor of the Urinary Bladder</condition>
  <condition>Cancer of the Bladder</condition>
  <arm_group>
    <arm_group_label>Non-Muscle Invasive Bladder Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be enrolled in sequential, dose escalating cohorts of NanoDoce direct injection (0.75 1.5, 2.5, or 3.75 mg/mL). Subjects will also receive an initial NanoDoce intravesical instillation at 2.0 or 3.0 mg/mL and additional Induction (6 weekly NanoDoce intravesical instillations, followed by 6 weeks of rest) and Maintenance (3 weekly NanoDoce intravesical instillations, followed by 9 weeks of rest) instillations at 2.0 or 3.0 mg/mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Muscle Invasive Bladder Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be enrolled in sequential, dose escalating cohorts of NanoDoce direct injection (0.75 1.5, 2.5, or 3.75 mg/mL). Subjects will also receive an initial NanoDoce intravesical instillation at 2.0 or 3.0 mg/mL. Subjects will then go on to receive institutional standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NanoDoce (direct injection)</intervention_name>
    <description>Subjects will receive NanoDoce injected into the index tumor resection site on the bladder wall, immediately following transurethral resection of the bladder tumor (TURBT)</description>
    <arm_group_label>Muscle Invasive Bladder Cancer</arm_group_label>
    <arm_group_label>Non-Muscle Invasive Bladder Cancer</arm_group_label>
    <other_name>docetaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NanoDoce (intravesical instillation) - Visit 2 Instillation</intervention_name>
    <description>All subjects will receive an initial intravesical instillation within 2 hours of direct injection.</description>
    <arm_group_label>Muscle Invasive Bladder Cancer</arm_group_label>
    <arm_group_label>Non-Muscle Invasive Bladder Cancer</arm_group_label>
    <other_name>docetaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Institutional Standard of Care</intervention_name>
    <description>Group 2 (MIBC) will receive institutional standard of care treatments after the Visit 2 intravesical instillation.</description>
    <arm_group_label>Muscle Invasive Bladder Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NanoDoce (intravesical instillation) - Induction and Maintenance Instillations</intervention_name>
    <description>Group 1 (NMIBC) will receive intravesical instillations in an Induction Period and a Maintenance Period.</description>
    <arm_group_label>Non-Muscle Invasive Bladder Cancer</arm_group_label>
    <other_name>docetaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent;

          -  Age ≥18 years;

          -  Patients with either:

               -  High-risk Non-Muscle Invasive Bladder Cancer (NMIBC);

               -  Muscle Invasive Bladder Cancer (MIBC);

          -  Urothelial carcinoma confirmed by biopsy, urine cytology, computed tomography scan
             (CT) or other institution-approved diagnostic methodology;

          -  All visible tumors removed during bladder resection (TURBT);

          -  Performance Status (ECOG) 0-2 at study entry;

          -  Life expectancy of at least 6 months;

          -  Adequate marrow, liver, and renal function;

               -  ANC ≥ 1.5 x 10^9/L;

               -  Hemoglobin ≥ 9.5 grams/dL;

               -  Platelets ≥ 75 x 10^9/L;

               -  Total bilirubin ≤ 1.5x institutional ULN;

               -  AST/ ALT ≤ 2.5x institutional ULN;

               -  Creatinine ≤ 1.5x institutional ULN;

          -  Adequate method of birth control.

        Exclusion Criteria:

          -  Metastatic disease;

          -  Previous (within 12 months) or concurrent history of non-bladder malignancy, except
             for non-melanoma skin cancer;

          -  Intravesical therapy within 6 weeks prior to consent (chemotherapy or immunotherapy
             including BCG administered directly into the bladder);

          -  Resection surface area greater than 8 cm2;

          -  Upper tract and urethral disease within 18 months;

          -  Known hypersensitivity to any of the study drug components or reconstitution
             components;

          -  Pregnant or breastfeeding;

          -  Participation in the treatment phase of another clinical trial within 3 months prior
             to consent;

          -  Investigator's opinion of subject's probable noncompliance or inability to understand
             the trial and/or give adequate informed consent;

          -  Ongoing drug or alcohol abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Lamm, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>BCG Oncology, PC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rose Marie Cavanna-Mast</last_name>
    <phone>805-595-1300</phone>
    <email>NANODOCE-2017-02@usbiotest.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>BCG Oncology, PC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Mobley</last_name>
      <phone>602-493-6626</phone>
      <email>debbi@bcgoncology.com</email>
    </contact>
    <investigator>
      <last_name>Donald L Lamm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Max Kates, MD</last_name>
      <phone>410-955-6100</phone>
      <email>mkates@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Max Kates, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget James, M.A.</last_name>
      <phone>212-304-5543</phone>
      <email>bb2771@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Guarionex Joel DeCastro, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Baiden, RN, CCRC</last_name>
      <phone>843-449-1010</phone>
      <email>jbaiden@curcmb.com</email>
    </contact>
    <investigator>
      <last_name>Neal Shore, MD, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Health San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Nijland</last_name>
      <phone>210-567-8554</phone>
      <email>NijlandK@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Ahmed Mansour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 14, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-muscle invasive bladder cancer</keyword>
  <keyword>muscle invasive bladder cancer</keyword>
  <keyword>high-risk bladder cancer</keyword>
  <keyword>BCG-unresponsive bladder cancer</keyword>
  <keyword>BCG failure</keyword>
  <keyword>BCG-refractory bladder cancer</keyword>
  <keyword>BCG-resistant bladder cancer</keyword>
  <keyword>NMIBC</keyword>
  <keyword>MIBC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Urogenital Neoplasms</mesh_term>
    <mesh_term>Urologic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

